Publication Type : Scientific reports
Source : Indian Journal of Medical and Paediatric Oncology. 2020 Mar;41(02):221-34.
Url : https://www.thieme-connect.com/products/ejournals/pdf/10.4103/ijmpo.ijmpo_1_20.pdf
Campus : Kochi
School : School of Medicine
Year : 2021
Abstract : Drug development in oncology has witnessed a revolutionary growth from its humble beginning with
nitrogen mustard in 1940 to immunotherapy in 1986 (Interferon alpha). The arsenal of cytotoxics
is ever increasing, contributing to better survival outcomes and improved quality of life. Over the
years, many cytotoxics have fallen out of favor too, due to its side effects and availability of drugs
with better efficacy and toxicity profile. Taxane, a microtubule stabilizing agent extracted from the
poisonous Yew tree, was discovered in 1964 and came into clinical use in 1992 with its approval
for ovarian cancer. This group has grown into a cornerstone of many treatment protocols, spanning
multiple tumor types. This review discusses in brief the salient features of cytotoxic agents in this
drug group, its history, physico‑chemical properties, mechanism of action, pharmacodynamics, and
pharmacokinetics. Though the benefits of taxanes are well understood, there are unique problems
associated with the use of taxanes and there is an expanding literature on taxane resistance. We
briefly look at the resistance mechanisms. There have been significant efforts to circumvent the
problems related to conventional taxanes, with an attempt at creating newer carrier molecules and
adjunct drugs with taxanes, which is slowly gaining traction in clinical practice.
Cite this Research Publication : Jose WM. Taxanes–The backbone of medical oncology. Indian Journal of Medical and Paediatric Oncology. 2020 Mar;41(02):221-34.